On October 19, 2016, the new drug Olaratumab passed the accelerated approval of the US FDA and could be combined with doxorubicin to treat specific types of soft tissue sarcoma (STS) in adults.
portant; word-wrap: break-word! important; outline: none 0px! important; “> In May this year, FDA granted Olaratumab priority review qualification. Olaratumab was originally designed to block the PDGFRα signaling pathway in tumor cells and microenvironment. In response to this mode of action, Olaratumab also passed the FDA“ breakthrough drug ” , “Fast Track” and “Orphan Drugs” approval.
portant; word-wrap: break-word! important; outline: none 0px! important; “> Olaratumab is a human-derived IgG1 monoclonal antibody that has a high targeting affinity for human platelet-derived growth factor receptor α (PDGFRα). Some studies have found that PDGFRα is found in various tumor tissue Expression, and the abnormal activation of this receptor has a certain relationship with tumors. Preclinical studies believe that PDGFRα may increase tumor proliferation and metastatic potential.
portant; word-wrap: break-word! important; outline: none 0px! important; “> Olaratumab is the first STS initial treatment drug after indosine and radiotherapy were approved more than 40 years ago. For these patients, the most commonly used treatment method was doxorubicin or Combine with other drugs.
portant; word-wrap: break-word! important; outline: none 0px! important; “> A clinical trial of 133 patients with metastatic STS containing 25 different tissue types evaluated the efficacy and safety of Olaratumab. The results of the study showed that Olaratumab combined with single-agent adriamycin treatment The survival of the patients in the adriamycin treatment group was significantly improved, with a median overall survival of 14.7 vs 26.5 months; a median progression-free survival of 4.4 vs 8.2 months; and tumor regression rates of 7.5% vs 18.2%, respectively.
portant; word-wrap: break-word! important; outline: none 0px! important; “> Olaratumab treatment has a risk of serious adverse events, including infusion-related reactions and embryo-fetal damage. Infusion-related reactions include hypotension, fever, chills, and rash. The most common treatment side effects are nausea, fatigue, and neutral Granulocytopenia, musculoskeletal pain, mucositis, hair loss, vomiting, diarrhea, loss of appetite, abdominal pain, neuropathy, and headache.
